Indoxyl Sulfate Promotes Proliferation of Human Aortic Smooth Muscle Cells by Inducing Oxidative Stress

Journal of Renal Nutrition

Volumn 19, Issue 1, 2009, Pages 29-32

  Muteliefu, Gulinuer ^a   Enomoto, Atsushi ^b   Niwa, Toshimitsu ^a  

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; INDICAN;

AORTA VALVE STENOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CELL CULTURE; CELL DIVISION; CHRONIC KIDNEY FAILURE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; HUMAN; MORTALITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; VASCULAR SMOOTH MUSCLE;

ANTIOXIDANTS; AORTIC VALVE STENOSIS; CARDIOVASCULAR DISEASES; CELL DIVISION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDICAN; KIDNEY FAILURE, CHRONIC; MUSCLE, SMOOTH, VASCULAR; OXIDATIVE STRESS;

RATTUS;

EID: 58049157534     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2008.10.014     Document Type: Article

References (28)

1. Foley R.N., Parfrey P.S., and Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 (1998) S112-S119
2. Johnson D.W., Craven A.M., and Isbel N.M. Modification of cardiovascular risk in hemodialysis patients: an evidence-based review. Hemodial Int 11 (2007) 1-14
3. Derici U. El Nahas AM: Vascular calcifications in uremia: old concepts and new insights. Semin Dial 19 (2006) 60-68
4. Niwa T. Uremic toxicity. Indoxyl sulfate. In: Massry S.G., and Glassock R.J. (Eds). : Textbook of nephrology (2001), Lippincott Williams & Wilkins, Philadelphia 1269-1272
5. Niwa T. Organic acids and the uremic syndrome: protein metabolite hypothesis in the progression of chronic renal failure. Semin Nephrol 16 (1996) 167-182
6. Niwa T., and Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 124 (1994) 96-104
7. Niwa T., Ise M., and Miyazaki T. Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. Am J Nephrol 14 (1994) 207-212
8. Niwa T., Takeda N., Tatematsu A., et al. Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography. Clin Chem 34 (1988) 2264-2267
9. Miyazaki T., Ise M., Seo H., et al. Indoxyl sulfate increases the gene expressions of TGF-β1, TIMP-1 and proα1(I) collagen in kidneys of uremic rats. Kidney Int 52 Suppl 62 (1997) S15-S22
10. 1 and progression of renal failure. Kidney Int 52 Suppl 63 (1997) S211-S214
11. Enomoto A., Takeda M., Tojo A., et al. Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol 13 (2002) 1711-1720
12. Owada S., Goto S., Bannai K., et al. Indoxyl sulfate reduces superoxide scavenging activity in the kidneys of normal and uremic rats. Am J Nephrol 28 (2008) 446-454
13. Adijiang A., Goto S., Uramoto S., et al. Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats. Nephrol Dial Transplant 23 (2008) 1892-1901
14. Gelasco A.K., and Raymond J.R. Indoxyl sulfate induces complex redox alterations in mesangial cells. Am J Physiol Renal Physiol 290 (2006) F1551-F1558
15. Motojima M., Hosokawa A., Yamato H., et al. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int 63 (2003) 1671-1680
16. Dou L., Bertrand E., Cerini C., et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 65 (2004) 442-451
17. Dou L., Jourde-Chiche N., Faure V., et al. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost 5 (2007) 1302-1308
18. Yamamoto H., Tsuruoka S., Ioka T., et al. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int 69 (2006) 1780-1785
19. Tepel M., van der Giet M., Statz M., et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 107 (2003) 992-995
20. Boaz M., Smetana S., Weinstein T., et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 356 9237 (2000) 1213-1218
21. Niwa T., Tsukushi S., Ise M., et al. Indoxyl sulfate and progression of renal failure: effects of low-protein diet and oral sorbent on indoxyl sulfate production in uremic rats and undialyzed uremic patients. Miner Electrol Metab 23 (1997) 179-184
22. Niwa T., Nomura T., Sugiyama S., et al. The protein metabolite hypothesis, a model for the progression of renal failure: An oral sorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int 52 Suppl 62 (1997) S23-S28
23. Miyazaki T., Aoyama I., Ise M., et al. An oral sorbent reduces overload of indoxyl sulfate and gene expression of TGF-β1 in uremic rat kidneys. Nephrol Dial Transplant 15 (2000) 1773-1781
24. Aoyama I., Shimokata K., and Niwa T. Combination therapy with benazepril and oral adsorbent ameliorates progressive renal fibrosis in uremic rats. Nephron 90 (2002) 297-312
25. Taki K., and Niwa T. Indoxyl sulfate-lowering capacity of oral sorbents affects prognosis of kidney function and oxidative stress in chronic kidney disease. J Ren Nutr 17 (2007) 48-52
26. Schulman G., Agarwal R., Acharya M., et al. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 47 (2006) 565-577
27. Shimoishi K., Anraku M., Kitamura K., et al. An oral absorbent, AST-120 protects against the progression of oxidative stress by reducing the accumulation of indoxyl sulfate in the systemic circulation in renal failure. Pharm Res 24 (2007) 1283-1289
28. Nakamura T., Kawagoe Y., Matsuda T., et al. Oral adsorbent AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. Kidney Blood Press Res 27 (2004) 121-126